EP Patent

EP2308493A1 — Ameliorating or therapeutic agent for dyslipidemia

Assigned to Mochida Pharmaceutical Co Ltd · Expires 2011-04-13 · 15y expired

What this patent protects

An ameliorating or therapeutic agent for dyslipidemia which is safe and has high effective and a method of using such an ameliorating or therapeutic agent are provided. The ameliorating or therapeutic agent for dyslipidemia includes at least one selected from the group consisting…

USPTO Abstract

An ameliorating or therapeutic agent for dyslipidemia which is safe and has high effective and a method of using such an ameliorating or therapeutic agent are provided. The ameliorating or therapeutic agent for dyslipidemia includes at least one selected from the group consisting of EPA and pharmaceutically acceptable salts and esters thereof and nicotinic acid or a pharmaceutically acceptable derivative thereof in combination as active ingredients .

Drugs covered by this patent

Patent Metadata

Patent number
EP2308493A1
Jurisdiction
EP
Classification
—
Expires
2011-04-13
Drug substance claim
No
Drug product claim
No
Assignee
Mochida Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.